Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adult MeSH
- Phenylurea Compounds administration & dosage MeSH
- Indoles administration & dosage MeSH
- Carcinoma, Renal Cell drug therapy mortality pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Kidney Neoplasms drug therapy mortality pathology MeSH
- Niacinamide administration & dosage analogs & derivatives MeSH
- Disease-Free Survival MeSH
- Disease Progression MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Pyrroles administration & dosage MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sorafenib MeSH
- Sunitinib MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Phenylurea Compounds MeSH
- Indoles MeSH
- Niacinamide MeSH
- Pyrroles MeSH
- Sorafenib MeSH
- Sunitinib MeSH
Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to first- versus second TKI was observed (p < 0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression-free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.
See more in PubMed
Ann Oncol. 2012 Feb;23(2):395-401 PubMed
N Engl J Med. 2007 Jan 11;356(2):115-24 PubMed
Lancet. 2008 Aug 9;372(9637):449-56 PubMed
Lancet. 2011 Dec 3;378(9807):1931-9 PubMed
N Engl J Med. 2007 Jan 11;356(2):125-34 PubMed
Target Oncol. 2013 Sep;8(3):203-209 PubMed
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy
